Scott Webster retweeted
... and on the same day here are the encouraging clinical trial results from the drug that we developed to reduce cortisol action in the brain of patients with dementia @prof_webster actinogen.com.au/
Scott Webster retweeted
Kynos is rapidly building momentum towards the clinic. Alison’s experience across large pharma and #biotech covers #finance at the #operational level as well as a #strategic outlook. A breadth of skill and experience to support Kynos achieve a strong position in the near future.
This Post is from an account that no longer exists. Learn more
Scott Webster retweeted
Enamine is resuming work.
Please review the new statement from our Founder and CEO, Andrey Tolmachev.
https://teapawt.net/t.co/o6kjNeW5lz
Scott Webster retweeted
"Supporting companies such as Kynos Therapeutics to progress its ground-breaking medical research is a priority for @scotent" - our Director of Growth Investments, Kerry Sharp on the @EdinburghUni spin-out's financing announcement today: https://teapawt.net/t.co/GNIFizi5lI
Scott Webster retweeted
New portfolio company @KynosTxLtd with @epidarex @scotent @DamianJMole @prof_webster. Excited to support & you can read more here: https://teapawt.net/t.co/E0FxIwJ0vf. #backinginnovation
👇
thetimes.co.uk/article/kynos…
Scott Webster retweeted
Great news on #WorldHealthDay with investment in new co @KynosTxLtd. Excited to support & you can read more here: https://teapawt.net/t.co/E0FxIwJ0vf. #backinginnovation @epidarex @scotent
👇
University of Edinburgh life sciences spin-out secures major £9m injection scotsman.com/business/univer…
Scott Webster retweeted
Kynos Therapeutics, a life sciences spin-out from @EdinburghUni, has emerged from 'stealth mode' with £9m to finance its next phase of growth insider.co.uk/news/edinburgh…
Scott Webster retweeted
2020 was a tough year, but our community at CVS still achieved so much! 🌟
Read about some of our Centre's 2020 accomplishments (awards, key research, and much more) here 👇
https://teapawt.net/t.co/ScbWrsv0jG
Scott Webster retweeted
could a non-segmented RNA virus rapidly evolve to evade a polyclonal immune response, rendering a vaccine ineffective?
I think if you'd asked the average RNA virus researcher a year ago, the answer would have been no
but then again, 2020 wasn't an average year ... 🧵1/n
Scott Webster retweeted
The whole thing is a fiasco. The 90% "arm" looks useless to me. So you'd be forced to judge this on the 62% rate. That relegates this vaccine to countries that can't afford a better vaccine. And the UK, which can.
$AZN So as we all call it The Astra trial which was messy with its error in dosing, it was actually The Oxford Covid Vaccine Trial Group who ran it. This also explains why there were so many arms and dosing regimens studied. It was an academic experiment. Astra didn’t mess up.
Scott Webster retweeted
Dave Newby nails the whole situation - we cant forget the pre-existing and continuing issues our critical research addresses.
ICYMI: @TheBHF's Professor David Newby talks to @ElsaMaishman @TheScotsman about the importance of protecting medical research to save and improve lives @EdinUniCVS @EdinburghUni @AMRC @EdinUniMedia scotsman.com/health/future-s…
Scott Webster retweeted
Due to the financial impact of Covid-19, @TheBHF has been forced to halve its research investment this year.
That could slow progress into preventing, diagnosing and treating heart & circulatory diseases.
That’s why @hmtreasury & @RishiSunak must support #ResearchAtRisk.














